Lunai Bioworks Inc. · NASDAQ:LNAI
Lunai Bioworks — Investor Presentation (January 2026)
31 slides from Lunai Bioworks's investor presentation, January 2026
Slide 1: Investor Overview
Decoding life. Discovering cures. INVESTOR OVERVIEW January 2026, NASDAQ: LNAI
Slide 2: Disclaimer and Forward-Looking Statements
Disclaimer and Forward-Looking Statements This presentation has been prepared by Lunai Bioworks, Inc. (“Lunai” or the “Company”) for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities. This presentation contains forward-looking st
Slide 3: Lunai Bioworks is a next-generation drug discovery company
LUNAI BIOWORKS IS A NEXT-GENERATION DRUG DISCOVERY COMPANY BUILT TO REDUCE CLINICAL RISK BY REVERSE-ENGINEERING DISEASE BIOLOGY • After more than $42.5 billion invested*, there are still no therapies that reverse Alzheimer’s or Parkinson’s disease. Why? Because these conditions are defined by shared
Slide 4: The $170B patent cliff driving urgent deal-making
The $170B patent cliff driving urgent deal-making Scale and urgency of the crisis $170B+ 70 90%+ Revenue at Risk Blockbuster Drugs Price Compression Annual pharmaceutical revenue facing generic Number of blockbuster products (each generating Typical revenue decline post-loss of exclusivity as compet
Slide 5: Lunai Unifies Biology, AI, and In Vivo Proof into One Discovery Engine
Lunai Unifies Biology, AI, and In Vivo Proof into One Discovery Engine The market imperative The biopharma industry is deploying massive capital into external innovation to address a looming ($170B) patent cliff. The strategic focus has shifted to de- risking biology before clinical investment Lunai
Slide 6: Lunai is unique in the precision medicine and drug discovery space
Lunai is unique in the precision medicine and drug discovery space We have a unique platform for data standardization and integration and are the only tech bio company that couples sophisticated AI predictions with scalable validation in living organisms. Experiments are efficiently driven through A
Slide 7: Lunai Augusta Platform vs Recursion and Insilico Medicine
Dimension Lunai – Augusta Platform Recursion Insilico Medicine Disease-first: clinical-grade patient Discovery Starting Point Molecule / phenotype-first Target / molecule-first biology Explicit deconstruction into Disease Understanding Implicit correlations Target-centric biological subtypes Reverse
Slide 8: Lunai's platform is disruptive and positioned for partnering
LUNAI’S PLATFORM IS DISRUPTIVE AND POSITIONED FOR PARTNERING Lunai’s Augusta platform inverts the traditional AI drug discovery paradigm. Instead of starting with molecules and searching for signals, Augusta reverse- Engineers’ disease biology from clinical-grade patient data, deconstructing complex
Slide 9: Biology is complex. The problem is lack of biological resolution
Biology is complex. The problem isn’t lack of investment; it’s lack of biological resolution. >90% Despite trillions invested, most therapies for complex diseases manage symptoms rather than cure disease, because they assume a single biology where none exists. of clinical trials fail, most due Lunai
Slide 10: The Augusta Platform – AI meets phenomics
The Augusta Platform – AI meets phenomics Patented AI process to group patients based on CLINICAL INSIGHTS phenotype, identify biomarkers, and prioritize therapeutic targets. Hundreds of proprietary models used to map PHENOGRAPH Phenotypes from the clinic to the experimental lab. AUGUSTA Quantifying
Slide 11: Phenograph
Phenograph The Phenograph enables quick translation between human clinical and model system phenotypes. It applies our patented ContingentAI process to fill in the whitespace of known gene-phenotype associations using machine learning. 77% 329 Of data is proprietary Gene-disease and AI-derived prior
Slide 12: Computer vision
Computer vision Speed to validation Zebrafish offer whole organism vertebrate biology, where genetic predictions are rapidly validated in vivo on our automated high- throughput platform. Combined with our proprietary Computer Vision software, speed to target validation and Hit ID can be achieved in
Slide 13: The Augusta Platform - Validation
The Augusta Platform - Validation CLINICAL INSIGHTS PHENOGRAPH AUGUSTA COMPUTER VISION CONTINGENT AI the patented core technology that deploys machine learning through automated pre-processing MOA MINER pipelines of thousands of models
Slide 14: Augusta Patent Protection
AUGUSTA PATENT PROTECTION • Our core IP addresses a fundamental challenge in drug discovery – data from siloed, disparate datasets can have inherent bias that confounds AI. Patent No Filing Date Status Description Next steps • We created a unique process for data processing and integration that allo
Slide 15: Lunai's broad CNS pipeline addresses a massive unmet need
Lunai’s broad CNS pipeline addresses a massive unmet need— neurological disorders affecting roughly 26% of Americans Parkinson’s Disease1 U.S. 1.1 million patients Worldwide >10 million patients Annual drug sales $7-7.5B Epilepsy2 U.S. 3.5 million patients Worldwide 50 million patients Annual drug s
Slide 16: Lunai identified sub-type specific biomarkers in Parkinson's Disease
Lunai identified 3 sub-type specific biomarkers in Parkinson’ Disease
Slide 17: Supernus partnership: epilepsy patient stratification and SPN-817
Assisted Supernus in stratifying Epilepsy patient sub-types that will respond to PA R T E R N S H I P Car the drug, SPN-817 Quantified effect of small molecule drug to reduce seizure phenotype in genetic models and predict patient responses Seizure Assay 0.07 0.06 PREDICTED ZEBRAFISH PHENOTYPE A
Slide 18: Deerfield partnership to discover and develop novel therapeutics
Deerfield partnership to discover and develop novel therapeutics Deerfield is an investment management firm and their 3DC group is an internal R&D organization that progresses novel therapeutic targets with a goal of out-licensing therapeutic assets to pharma companies at the preclinical or clinic
Slide 19: NIH STTR grant allows for increased experimental capacity
NIH STTR grant allows for increased experimental capacity BioSymetrics (a subsidiary of Lunai Bioworks) received a fast-tracked Phase I/II STTR grant in August 2025 to identify novel therapeutics for Alcohol Use Disorder (AUD) using its AI-based zebrafish platform. This $1.85M grant, shared with Bri
Slide 20: Revenue Model: De-Risked CNS Assets for Pharma Partnership & Licensing
Revenue Model: De-Risked CNS Assets for Pharma Partnership & Licensing Lunai is uniquely positioned to address pharma’s neuroscience patent cliff by delivering de-risked CNS assets with clean IP, validated biology, and precision medicine alignment. Our platform generates the exact criteria pharma us
Slide 21: What We Sell: Partner-Ready CNS Discovery Outputs
What We Sell: Partner-Ready CNS Discovery Outputs Delivering partner-ready biology, biomarkers, and assets from real-world and clinical data. Patient Subtyping & Disease Stratification Biomarker Discovery & Trial Ready endpoints In Vivo–Validated Small-Molecule Assets Identify hidden patient sub-gro
Slide 22: 2024 Neurology R&D deals and Lunai's pre-clinical licensing model
2024 NEUROLOGY R&D: 59 DEALS, $36.5B TOTAL VALUE, $2.6B UPFRONT * LUNAI USES A PRE-CLINICAL LICENSING MODEL DESIGNED FOR SUBSTANTIAL REVENUES *Dataform: Neurologic R&D Partnerships, M&A, Ventures, and IPOs in 2024 By Mohteshim Ashraf Apr 14, 2025
Slide 23: Biodefense
BIODEFENSE THE SAME PLATFORM THAT DE-RISKS CNS DRUG DISCOVERY CAN RAPIDLY DETECT, ANALYZE, AND COUNTER EMERGING CHEMICAL AND BIOLOGICAL THREATS The Problem Lunai’s Advantage Why It Matters Modern Threats Are Evolving Faster Augusta Was Built for Exactly This High Urgency. High Budgets. Non- Than Tra
Slide 24: Biodefense Execution and Revenue Model
BIODEFENSE EXECUTION AND REVENUE MODEL BIODEFENSE MONETIZES SPEED, BIOLOGY, AND CERTAINTY — THE SAME ASSETS PHARMA VALUES IN CNS. Step 1: Threat Analysis Step 2: Countermeasure Identification Step 3: In Vivo Validation Rapid assessment of novel chemical Screens: •Confirms efficacy and toxicity in or
Slide 25: Other Programs: Dendritic Cell Cancer Therapy (DCCT) Overview
Other Programs: Currently In Partnership Discussions Dendritic Cell Cancer Therapy (DCCT) Overview Lunai DCCT represents a next-generation dendritic cell (DC) immunotherapy platform, leveraging allogeneic CD34+ HSC-derived DCs engineered to enhance immune activation and durability. Off-the-Shelf Sca
Slide 26: The DCCT is a unique, scalable cell therapy for solid tumors
The DCCT is a unique, scalable cell therapy for solid tumors • Patent protected, with two peer reviewed publications outlining the approach and efficacy1, 2 • Two humanized mouse models show reduction/ablation of pancreatic tumors • Pre-IND meeting with the FDA did not identify any hurdles to Phase
Slide 27: 2026 Revenue Catalysts
2026 REVENUE CATALYSTS Pharma Revenue Secure 6 CNS partnerships for: Parkinson’s Epilepsy Alzheimer’s Secure 1 oncology partnership Out-license our immunotherapy program for oncology Non-dilutive / government revenue Receive a government contract for biodefense Release findings on chemical
Slide 28: The Lunai Executive Team
The Lunai Executive Team David Weinstein, CEO Nathen Fuentes, CFO Gabe Musso, PhD, CSO (BioSymetrics) • Appointed by the board of directors as CEO in • Appointed as CFO in January of 2025 • Co-founder and Chief Scientific Officer of October 2024 BioSymetrics (acquired by Lunai in 2025), a • Previous
Slide 29: Board of Directors
Douglas Calder Mark Collins, PhD James McNulty • President and a director of Vycellix, Inc and its • 40-year career leveraging computers in drug • CFO for MIRALOGX, LLC, a privately held subsidiaries and affiliates since 2015 discovery, blending biology, AI, and software incubator which develops and
Slide 30: Capital Market Summary
Capital Market Summary News Releases LNAI • December 9, 2025 • Lunai Bioworks Identifies Three Parkinson's Subtypes and Prioritized Drug Targets to Accelerate Proof-of-Concept Programs NASDAQ Listed and Strategic Partnerships in a $13B Market • November 25, 2025 • Lunai Bioworks Secures First Licens
Slide 31: Decoding life. Discovering cures.
Decoding life. Discovering cures. Gabe Musso, PhD CSO gabe@lunaibioworks.com www.lunaibioworks.com NASDAQ: LNAI
Lunai Bioworks — Investor Presentation (January 2026) on 6ix